Auxiliary Diagnosis and Prognostic Value of Dehydrogenase/Reductase 2 (DHRS2) in Various Tumors
-
Zhongwu An
,
Weibo Bo
,
Jibao Qin
,
Ling Jiang
,
Jie Jiang
Abstract
Background: As the most convenient and commonly used for clinical diagnosis, cancer biomarker has been widely used in the auxiliary diagnosis of tumors, the observation of curative effect, the judgment of prognosis, and the monitoring of the disease.
Methods: Pan-cancer analysis was used to validate the value of Dehydrogenase/Reductase 2 (DHRS2) as a tumor prognostic marker in various tumors. The relationship of DHRS2 to TMB and MSI was used to explain the effect of DHRS2 on genomic instability. Online cbioportal was used to analyze DHRS2 mutations in tumors. Finally, 33 clinical tumor samples were collected in 2021 who were enrolled into the Affiliated Lianyungang Oriental Hospital of Xuzhou Medical University, to verify the expression and diagnostic prognostic value of DHRS2.
Results: The expression of DHRS2 was up-regulated in a variety of tumors and had adverse effects on the overall survival, disease-free interval, and progression-free interval of tumor patients. DHRS2 was associated with tumor genome instability, confirming that DHRS2 was correlated with tumorigenesis. In addition, DHRS2 had different mutation sites in various tumors. DHRS2 was up-regulated and was a poor prognosis biomarker in clinical tumor samples.
Conclusion: DHRS2 was aberrantly expressed in tumors and has diagnostic prognostic value.
1. Mukherji D, Murillo RH, Van Hemelrijck M, et al (2021). Global cancer research in the post-pandemic world. Lancet Oncol, 22(12):1652-4.
2. Dyba T, Randi G, Bray F, et al (2021). The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers. Eur J Cancer, 157:308-47.
3. Niu B, Liao K, Zhou Y, et al (2021). Application of glutathione depletion in cancer therapy: Enhanced ROS-based therapy, ferroptosis, and chemotherapy. Biomaterials, 277:121110.
4. Wu L, Qu X (2015). Cancer biomarker detection: recent achievements and challenges. Chem Soc Rev, 44(10):2963-97.
5. Lindgren M, Jansson M, Tavelin B, Dirix L, Vermeulen P, Nystrom H (2021). Type IV collagen as a potential biomarker of metastatic breast cancer. Clin Exp Metastasis, 38(2):175-85.
6. Zhang M, Cheng S, Jin Y, Zhao Y, Wang Y (2021). Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer. Biochim Biophys Acta Rev Cancer, 1875(2):188503.
7. Liu T, Li X, Liu D, Liu S, Dong M (2021). Increased serum CA125 II, but not CEACA19-9AFP or CA72-4 in colon cancer compared to rectal cancer. Br J Biomed Sci, 78(4):218-20.
8. Choy CT, Wong CH, Chan SL (2018). Embedding of Genes Using Cancer Gene Expression Data: Biological Relevance and Potential Application on Biomarker Discovery. Front Genet, 9:682.
9. Shi Y, Xu S, Ngoi NYL, Hui Y, Ye Z (2021). Rag GTPases suppress PRL-3 degradation and predict poor clinical diagnosis of cancer patients with low PRL-3 mRNA expression. Biochem Biophys Res Commun, 576:108-16.
10. Grunnet M, Sorensen JB (2012). Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer, 76(2):138-43.
11. O'Connor JP, Aboagye EO, Adams JE, et al (2017). Imaging biomarker roadmap for cancer studies. Nat Rev Clin Oncol, 14(3):169-86.
12. van Houdt PJ, Saeed H, Thorwarth D, et al (2021). Integration of quantitative imaging biomarkers in clinical trials for MR-guided radiotherapy: Conceptual guidance for multicentre studies from the MR-Linac Consortium Imaging Biomarker Working Group. Eur J Cancer, 153:64-71.
13. Miao Y, Wang J, Li Q, et al (2020). Prognostic value and immunological role of PDCD1 gene in pan-cancer. Int Immunopharmacol, 89(Pt B):107080.
14. Nettersheim D, Berger D, Jostes S, Skowron M, Schorle H (2019). Deciphering the molecular effects of romidepsin on germ cell tumours: DHRS2 is involved in cell cycle arrest but not apoptosis or induction of romidepsin effectors. J Cell Mol Med, 23(1):670-9.
15. Li JM, Jiang GM, Zhao L, et al (2019). Dehydrogenase/reductase SDR family member 2 silencing sensitizes an oxaliplatinresistant cell line to oxaliplatin by inhibiting excision repair crosscomplementing group 1 protein expression. Oncol Rep, 42(5):1725-34.
16. Cheerla N, Gevaert O (2017). MicroRNA based Pan-Cancer Diagnosis and Treatment Recommendation. BMC Bioinformatics, 18(1):32.
17. Mattiuzzi C, Lippi G (2020). Cancer statistics: a comparison between World Health Organization (WHO) and Global Burden of Disease (GBD). Eur J Public Health, 30(5):1026-7.
18. Walcher L, Kistenmacher AK, Suo H, et al (2020). Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies. Front Immunol, 11:1280.
19. Gabrielli F, Tofanelli S (2012). Molecular and functional evolution of human DHRS2 and DHRS4 duplicated genes. Gene, 511(2):461-9.
20. Shimonosono M, Idichi T, Seki N, (2019). Molecular pathogenesis of esophageal squamous cell carcinoma: Identification of the antitumor effects of miR1453p on gene regulation. Int J Oncol, 2019;54(2):673-88.
21. Yamada H, Arakawa Y, Saito S, Agawa M, Kano Y, Horiguchi-Yamada J (2006). Depsipeptide-resistant KU812 cells show reversible P-glycoprotein expression, hyper-acetylated histones, and modulated gene expression profile. Leuk Res, 30(6):723-34.
22. Han Y, Song C, Wang J, Tang H, Peng Z, Lu S (2018). HOXA13 contributes to gastric carcinogenesis through DHRS2 interacting with MDM2 and confers 5-FU resistance by a p53-dependent pathway. Mol Carcinog, 57(6):722-34.
23. Luo X, Li N, Zhao X, et al (2019). DHRS2 mediates cell growth inhibition induced by Trichothecin in nasopharyngeal carcinoma. J Exp Clin Cancer Res, 38(1):300.
24. Han Y, Wang Z, Sun S, et al (2020). Decreased DHRS2 expression is associated with HDACi resistance and poor prognosis in ovarian cancer. Epigenetics, 15(1-2):122-33.
25. Oda T, Sekimoto T, Kurashima K, Fujimoto M, Nakai A, Yamashita T (2018). Acute HSF1 depletion induces cellular senescence through the MDM2-p53-p21 pathway in human diploid fibroblasts. J Cell Sci, 131(9).
26. Kruiswijk F, Labuschagne CF, Vousden KH (2015). p53 in survival, death and metabolic health: a lifeguard with a licence to kill. Nat Rev Mol Cell Biol, 16(7):393-405.
27. Liu YC, Chang PY, Chao CC (2015). CITED2 silencing sensitizes cancer cells to cisplatin by inhibiting p53 trans-activation and chromatin relaxation on the ERCC1 DNA repair gene. Nucleic Acids Res, 43(22):10760-81.
28. Heinz S, Krause SW, Gabrielli F, Wagner HM, Andreesen R, Rehli M (2002). Genomic organization of the human gene HEP27: alternative promoter usage in HepG2 cells and monocyte-derived dendritic cells. Genomics, 79(4):608-15.
29. Bagaev A, Kotlov N, Nomie K, et al (2021). Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell, 39(6):845-65 e7.
2. Dyba T, Randi G, Bray F, et al (2021). The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers. Eur J Cancer, 157:308-47.
3. Niu B, Liao K, Zhou Y, et al (2021). Application of glutathione depletion in cancer therapy: Enhanced ROS-based therapy, ferroptosis, and chemotherapy. Biomaterials, 277:121110.
4. Wu L, Qu X (2015). Cancer biomarker detection: recent achievements and challenges. Chem Soc Rev, 44(10):2963-97.
5. Lindgren M, Jansson M, Tavelin B, Dirix L, Vermeulen P, Nystrom H (2021). Type IV collagen as a potential biomarker of metastatic breast cancer. Clin Exp Metastasis, 38(2):175-85.
6. Zhang M, Cheng S, Jin Y, Zhao Y, Wang Y (2021). Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer. Biochim Biophys Acta Rev Cancer, 1875(2):188503.
7. Liu T, Li X, Liu D, Liu S, Dong M (2021). Increased serum CA125 II, but not CEACA19-9AFP or CA72-4 in colon cancer compared to rectal cancer. Br J Biomed Sci, 78(4):218-20.
8. Choy CT, Wong CH, Chan SL (2018). Embedding of Genes Using Cancer Gene Expression Data: Biological Relevance and Potential Application on Biomarker Discovery. Front Genet, 9:682.
9. Shi Y, Xu S, Ngoi NYL, Hui Y, Ye Z (2021). Rag GTPases suppress PRL-3 degradation and predict poor clinical diagnosis of cancer patients with low PRL-3 mRNA expression. Biochem Biophys Res Commun, 576:108-16.
10. Grunnet M, Sorensen JB (2012). Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer, 76(2):138-43.
11. O'Connor JP, Aboagye EO, Adams JE, et al (2017). Imaging biomarker roadmap for cancer studies. Nat Rev Clin Oncol, 14(3):169-86.
12. van Houdt PJ, Saeed H, Thorwarth D, et al (2021). Integration of quantitative imaging biomarkers in clinical trials for MR-guided radiotherapy: Conceptual guidance for multicentre studies from the MR-Linac Consortium Imaging Biomarker Working Group. Eur J Cancer, 153:64-71.
13. Miao Y, Wang J, Li Q, et al (2020). Prognostic value and immunological role of PDCD1 gene in pan-cancer. Int Immunopharmacol, 89(Pt B):107080.
14. Nettersheim D, Berger D, Jostes S, Skowron M, Schorle H (2019). Deciphering the molecular effects of romidepsin on germ cell tumours: DHRS2 is involved in cell cycle arrest but not apoptosis or induction of romidepsin effectors. J Cell Mol Med, 23(1):670-9.
15. Li JM, Jiang GM, Zhao L, et al (2019). Dehydrogenase/reductase SDR family member 2 silencing sensitizes an oxaliplatinresistant cell line to oxaliplatin by inhibiting excision repair crosscomplementing group 1 protein expression. Oncol Rep, 42(5):1725-34.
16. Cheerla N, Gevaert O (2017). MicroRNA based Pan-Cancer Diagnosis and Treatment Recommendation. BMC Bioinformatics, 18(1):32.
17. Mattiuzzi C, Lippi G (2020). Cancer statistics: a comparison between World Health Organization (WHO) and Global Burden of Disease (GBD). Eur J Public Health, 30(5):1026-7.
18. Walcher L, Kistenmacher AK, Suo H, et al (2020). Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies. Front Immunol, 11:1280.
19. Gabrielli F, Tofanelli S (2012). Molecular and functional evolution of human DHRS2 and DHRS4 duplicated genes. Gene, 511(2):461-9.
20. Shimonosono M, Idichi T, Seki N, (2019). Molecular pathogenesis of esophageal squamous cell carcinoma: Identification of the antitumor effects of miR1453p on gene regulation. Int J Oncol, 2019;54(2):673-88.
21. Yamada H, Arakawa Y, Saito S, Agawa M, Kano Y, Horiguchi-Yamada J (2006). Depsipeptide-resistant KU812 cells show reversible P-glycoprotein expression, hyper-acetylated histones, and modulated gene expression profile. Leuk Res, 30(6):723-34.
22. Han Y, Song C, Wang J, Tang H, Peng Z, Lu S (2018). HOXA13 contributes to gastric carcinogenesis through DHRS2 interacting with MDM2 and confers 5-FU resistance by a p53-dependent pathway. Mol Carcinog, 57(6):722-34.
23. Luo X, Li N, Zhao X, et al (2019). DHRS2 mediates cell growth inhibition induced by Trichothecin in nasopharyngeal carcinoma. J Exp Clin Cancer Res, 38(1):300.
24. Han Y, Wang Z, Sun S, et al (2020). Decreased DHRS2 expression is associated with HDACi resistance and poor prognosis in ovarian cancer. Epigenetics, 15(1-2):122-33.
25. Oda T, Sekimoto T, Kurashima K, Fujimoto M, Nakai A, Yamashita T (2018). Acute HSF1 depletion induces cellular senescence through the MDM2-p53-p21 pathway in human diploid fibroblasts. J Cell Sci, 131(9).
26. Kruiswijk F, Labuschagne CF, Vousden KH (2015). p53 in survival, death and metabolic health: a lifeguard with a licence to kill. Nat Rev Mol Cell Biol, 16(7):393-405.
27. Liu YC, Chang PY, Chao CC (2015). CITED2 silencing sensitizes cancer cells to cisplatin by inhibiting p53 trans-activation and chromatin relaxation on the ERCC1 DNA repair gene. Nucleic Acids Res, 43(22):10760-81.
28. Heinz S, Krause SW, Gabrielli F, Wagner HM, Andreesen R, Rehli M (2002). Genomic organization of the human gene HEP27: alternative promoter usage in HepG2 cells and monocyte-derived dendritic cells. Genomics, 79(4):608-15.
29. Bagaev A, Kotlov N, Nomie K, et al (2021). Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell, 39(6):845-65 e7.
| Files | ||
| Issue | Vol 52 No 6 (2023) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/ijph.v52i6.12957 | |
| Keywords | ||
| Dehydrogenase/Reductase 2 Pan-cancer Diagnostic Prognostic marker | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
An Z, Bo W, Qin J, Jiang L, Jiang J. Auxiliary Diagnosis and Prognostic Value of Dehydrogenase/Reductase 2 (DHRS2) in Various Tumors. Iran J Public Health. 2023;52(6):1150-1160.
